NuCana plc Sponsored ADR ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für NuCana plc Sponsored ADR zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um NuCana plc Sponsored ADR zu Deinem Portfolio hinzuzufügen.
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) anno...
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listin...
EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on or about ...
NuCana (NASDAQ: NCNA ) stock is rising on Wednesday as the clinical-stage biopharmaceutical company's shares experience heavy trading this morning. That has more than 9.6 million shares of the company's stock changing hands as of this writing.
EDINBURGH, United Kingdom, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at TD Cowen's 44th Annual Health Care Conference.
NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to believe that NCNA's current lead candidate, NUC-3373, will be successful. NUC-3373 aims to replace 5-fluorouracil (5FU) by overcoming its numerous limitations. Notably, 5FU is still used in a variet...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.